{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:04:19Z","timestamp":1782968659140,"version":"3.54.5"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.pupt.2017.10.001","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T04:47:25Z","timestamp":1507006045000},"page":"88-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study"],"prefix":"10.1016","volume":"48","author":[{"given":"Janis K.","family":"Shute","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigino","family":"Calzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Cardaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"di Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive P.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2017.10.001_bib1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(07)61377-4","article-title":"BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study","volume":"370","author":"Buist","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2017.10.001_bib2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1517\/14656566.2016.1155555","article-title":"Treatment options for moderate-to-very severe chronic obstructive pulmonary disease","volume":"17","author":"Cazzola","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.pupt.2017.10.001_bib3","series-title":"Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD, Updated 2015)","author":"GOLD","year":"2015"},{"key":"10.1016\/j.pupt.2017.10.001_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ccm.2013.10.005","article-title":"Bronchodilators: current and future","volume":"35","author":"Cazzola","year":"2014","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.pupt.2017.10.001_bib5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2015.05.020","article-title":"Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy","volume":"761","author":"Calzetta","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pupt.2017.10.001_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/14740338.2015.1001363","article-title":"Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease","volume":"14","author":"Matera","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pupt.2017.10.001_bib7","first-page":"1","article-title":"Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis","volume":"20","author":"Rogliani","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pupt.2017.10.001_bib8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","article-title":"Pharmacology and therapeutics of bronchodilators","volume":"64","author":"Cazzola","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pupt.2017.10.001_bib9","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1183\/09031936.00213711","article-title":"Emerging anti-inflammatory strategies for COPD","volume":"40","author":"Cazzola","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.10.001_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1183\/09031936.00003814","article-title":"Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease","volume":"44","author":"Page","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.10.001_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1586\/17476348.2016.1121105","article-title":"Oxidation pathway and exacerbations in COPD: the role of NAC","volume":"10","author":"Matera","year":"2016","journal-title":"Expert Rev. Respir. Med."},{"issue":"371","key":"10.1016\/j.pupt.2017.10.001_bib12","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","article-title":"Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study","volume":"14","author":"Zheng","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2017.10.001_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00711-2017","article-title":"Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study","volume":"50","author":"Dal Negro","year":"2017","journal-title":"Eur. Resp. J."},{"key":"10.1016\/j.pupt.2017.10.001_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of heparin and related drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pupt.2017.10.001_bib15","doi-asserted-by":"crossref","first-page":"L1240","DOI":"10.1152\/ajplung.00206.2007","article-title":"Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis","volume":"293","author":"Broughton-Head","year":"2007","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.pupt.2017.10.001_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B","article-title":"Heparin-protein interactions","volume":"41","author":"Capila","year":"2002","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.pupt.2017.10.001_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pupt.2006.04.004","article-title":"Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination","volume":"19","author":"Brown","year":"2006","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2017.10.001_bib18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1183\/09031936.02.00105202","article-title":"Effect of inhaled heparin on lung function and coagulation in healthy volunteers","volume":"19","author":"Bendstrup","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.10.001_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/jamp.2009.0780","article-title":"Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis","volume":"23","author":"Markart","year":"2010","journal-title":"J.\u00a0Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.pupt.2017.10.001_bib20","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1164\/ajrccm.153.6.8665036","article-title":"Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma","volume":"153","author":"Diamant","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2017.10.001_bib21","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/cc6894","article-title":"A\u00a0phase 1 trial of nebulised heparin in acute lung injury","volume":"12","author":"Dixon","year":"2008","journal-title":"Crit. Care"},{"key":"10.1016\/j.pupt.2017.10.001_bib22","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1164\/ajrccm.153.5.8630624","article-title":"Time course of the protective effect of inhaled heparin on exercise-induced asthma","volume":"153","author":"Garrigo","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2017.10.001_bib23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1183\/09031936.06.00069005","article-title":"Inhaled heparin in cystic fibrosis","volume":"27","author":"Serisier","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.10.001_bib24","first-page":"449","article-title":"The effect of heparin aerosols on airway conductance in patients with chronic obstructive pulmonary disease","volume":"99","author":"Youngchaiyud","year":"1969","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.pupt.2017.10.001_bib25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.thromres.2015.10.011","article-title":"Inhalational use of antithrombotics in humans: review of the literature","volume":"136","author":"Monagle","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.pupt.2017.10.001_bib26","first-page":"507151","article-title":"Anti-inflammatory effects of heparin and its derivatives: a systematic review","volume":"2015","author":"Mousavi","year":"2015","journal-title":"Adv. Pharmacol. Sci."},{"key":"10.1016\/j.pupt.2017.10.001_bib27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1042\/bj2090455","article-title":"Binding of platelet factor 4 to heparin oligosaccharides","volume":"209","author":"Denton","year":"1983","journal-title":"Biochem. J."},{"key":"10.1016\/j.pupt.2017.10.001_bib28","first-page":"139","article-title":"Clinical issues of mucus accumulation in COPD","volume":"9","author":"Ramos","year":"2014","journal-title":"Int. J. COPD"},{"issue":"3","key":"10.1016\/j.pupt.2017.10.001_bib29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.rmed.2009.10.005","article-title":"Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study","volume":"104","author":"Pasqua","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2017.10.001_bib30","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.10.001_bib31","doi-asserted-by":"crossref","unstructured":"Malik SK, Jenkins DE. Alterations in airway dynamics following inhalation of ultrasonic mist. Chest; 62: 660\u2013664.","DOI":"10.1378\/chest.62.6.660"},{"key":"10.1016\/j.pupt.2017.10.001_bib32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/sj.bjp.0707364","article-title":"Novel uses for anti-platelet agents as anti-inflammatory drugs","volume":"152","author":"Pitchford","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pupt.2017.10.001_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/COPD.S4854","article-title":"Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation","volume":"4","author":"Bathoorn","year":"2009","journal-title":"Int. J. COPD"},{"key":"10.1016\/j.pupt.2017.10.001_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1465-9921-7-29","article-title":"Antimicrobial proteins and polypeptides in pulmonary innate defence","volume":"7","author":"Rogan","year":"2006","journal-title":"Resp. Res."},{"key":"10.1016\/j.pupt.2017.10.001_bib35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1378\/chest.10-2760","article-title":"Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD","volume":"140","author":"Parameswaran","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2017.10.001_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","article-title":"Inflammatory mechanisms in patients with chronic obstructive pulmonary disease","volume":"138","author":"Barnes","year":"2016","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2017.10.001_bib37","first-page":"528","volume":"vol. 206","author":"Jacques","year":"1979"},{"key":"10.1016\/j.pupt.2017.10.001_bib38","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(76)91679-2","article-title":"Intrapulmonary heparin. A new procedure for anticoagulant therapy","volume":"308","author":"Jaques","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2017.10.001_bib39","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/jth.13003","article-title":"Heparin enhances uptake of platelet factor 4\/heparin complexes by monocytes and macrophages","volume":"13","author":"Joglekar","year":"2015","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.pupt.2017.10.001_bib40","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1164\/ajrccm.160.5.9809123","article-title":"Lung deposition andclearance of inhaled (99m)Tc-heparin in healthy volunteers","volume":"160","author":"Bendstrup","year":"1999","journal-title":"Am. J. Respir. Crit. CareMed"},{"key":"10.1016\/j.pupt.2017.10.001_bib41","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/COPD.S22896","article-title":"A\u00a0pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion","volume":"6","author":"Chakravorty","year":"2011","journal-title":"Int. J. COPD"},{"key":"10.1016\/j.pupt.2017.10.001_bib42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/resp.12782","article-title":"Non-pharmacological treatments for COPD","volume":"21","author":"Mulhall","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.pupt.2017.10.001_bib43","first-page":"S2","article-title":"BTS guidelines on pulmonary rehabilitation in adults","volume":"68","year":"2013","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.pupt.2017.10.001_bib44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000448847","article-title":"Improvements in lung diffusion capacity following pulmonary rehabilitation in COPD with and without ventilation inhomogeneity","volume":"92","author":"Santus","year":"2016","journal-title":"Respiration"},{"issue":"4","key":"10.1016\/j.pupt.2017.10.001_bib45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000436979","article-title":"Effect of a three-week inpatient rehabilitation program on 544 consecutive patients with very severe COPD: a retrospective analysis","volume":"90","author":"Greulich","year":"2015","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2017.10.001_bib46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1155\/2004\/828591","article-title":"A\u00a0randomized trial to evaluate the sustained efficacy of a mucus clearance device in ambulatory patients with chronic obstructive pulmonary disease","volume":"11","author":"Wolkove","year":"2004","journal-title":"Can. Respir. J."},{"key":"10.1016\/j.pupt.2017.10.001_bib47","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.rmed.2011.02.003","article-title":"Cough and sputum production as risk factors for poor outcomes in patients with COPD","volume":"105","author":"Miravitlles","year":"2011","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2017.10.001_bib48","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40265-014-0235-3","article-title":"Targeting mucus hypersecretion: new therapeutic opportunities for COPD?","volume":"74","author":"Martin","year":"2014","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.pupt.2017.10.001_bib49","first-page":"CD001287","article-title":"Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease","author":"Poole","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pupt.2017.10.001_bib50","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1183\/16000617.00002215","article-title":"Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis","volume":"24","author":"Cazzola","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.pupt.2017.10.001_bib51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.coph.2012.01.015","article-title":"Antioxidant pharmacological therapies for COPD","volume":"12","author":"Rahman","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.pupt.2017.10.001_bib52","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1081\/COPD-200050655","article-title":"Minimally clinically important difference for the UCSD shortness of breath questionnaire, Borg scale, and visual analog scale","volume":"2","author":"Ries","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.pupt.2017.10.001_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1081\/COPD-200050527","article-title":"Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test","volume":"2","author":"Wise","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.pupt.2017.10.001_bib54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"Laboratories ATSCoPSfCPF","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2017.10.001_bib55","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1183\/09031936.02.00301002","article-title":"Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study","volume":"20","author":"Eaton","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.10.001_bib56","doi-asserted-by":"crossref","first-page":"194S","DOI":"10.1042\/bst024194s","article-title":"The antioxidant activity of heparins","volume":"24","author":"Grant","year":"1996","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.pupt.2017.10.001_bib57","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1042\/bj2520515","article-title":"Inhibition of leucocyte elastase by heparin and its derivatives","volume":"252","author":"Redini","year":"1988","journal-title":"Biochem. J."},{"issue":"Suppl 2","key":"10.1016\/j.pupt.2017.10.001_bib58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2047-783X-15-S2-27","article-title":"Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatment","volume":"4;15","author":"Demkow","year":"2010","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.pupt.2017.10.001_bib59","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1183\/09031936.00120609","article-title":"Therapeutic implications of the pathophysiology of COPD","volume":"35","author":"Macklem","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.10.001_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1094-5539(02)00174-8","article-title":"Mechanisms of bronchopulmonary C-fiber hypersensitivity induced by cationic proteins","volume":"16","author":"Lee","year":"2003","journal-title":"Pulmon Pharmacol. Ther."}],"container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455391730192X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455391730192X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T12:45:37Z","timestamp":1603025137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109455391730192X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":60,"alternative-id":["S109455391730192X"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2017.10.001","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2017.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}